Crow T J, Cross A J, Cooper S J, Deakin J F, Ferrier I N, Johnson J A, Joseph M H, Owen F, Poulter M, Lofthouse R
Neuropharmacology. 1984 Dec;23(12B):1561-9. doi: 10.1016/0028-3908(84)90100-x.
In patients with Alzheimer-type dementia, in addition to the well-known losses of cholinergic neurones, there is evidence of degeneration of the noradrenergic and serotonergic innervation of the cerebral cortex. While noradrenergic and cholinergic receptors are preserved there is a loss of serotonin S1 and S2 receptors, particularly in the temporal lobe. The loss of serotonin S2 receptors may occur at an early stage of the disease and, in temporal and frontal cortex, is correlated with the loss of somatostatin immunoreactivity. In patients dying in hospital with depression, and in individuals committing suicide, there are no consistent changes in monoamine metabolites. Noradrenergic, serotonergic, and other neurotransmitter receptors were found to be unchanged, although there was a moderate decrease in imipramine binding in a small group (n = 6) of subjects with a history of depression, who had committed suicide.
在阿尔茨海默型痴呆患者中,除了众所周知的胆碱能神经元丧失外,还有证据表明大脑皮质的去甲肾上腺素能和5-羟色胺能神经支配发生退化。虽然去甲肾上腺素能和胆碱能受体得以保留,但5-羟色胺S1和S2受体有所丧失,尤其是在颞叶。5-羟色胺S2受体的丧失可能发生在疾病的早期阶段,并且在颞叶和额叶皮质中,与生长抑素免疫反应性的丧失相关。在医院中因抑郁症死亡的患者以及自杀个体中,单胺代谢产物没有一致的变化。尽管一小群(n = 6)有抑郁症病史且已自杀的受试者中丙咪嗪结合有中度下降,但去甲肾上腺素能、5-羟色胺能及其他神经递质受体未发现有变化。